Analysts Offer Predictions for Nicox S.A.’s Q2 2024 Earnings (OTCMKTS:NICXF)

Nicox S.A. (OTCMKTS:NICXF) – Equities research analysts at HC Wainwright lowered their Q2 2024 earnings estimates for shares of Nicox in a research report issued to clients and investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.09) per share for the quarter, down from their prior forecast of ($0.08). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q1 2024 earnings at ($0.03) EPS, Q3 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.26) EPS.

Nicox Stock Performance

NICXF opened at $0.44 on Thursday. Nicox has a fifty-two week low of $0.44 and a fifty-two week high of $0.44. The firm’s fifty day moving average is $0.44 and its 200 day moving average is $0.52.

About Nicox

Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.